Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alprostadil in Acute Ischemic Stroke
NCT03252626Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 4, randomised, double-blind trial of Alprostadil Liposomes for Injection in ischemic stroke (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Modified Rankin Scale at 90 days. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Alprostadil Liposomes for Injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03252626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252626.